{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "63-year-old female presented with fecal incontinence, debilitating headaches, right arm weakness, gait instability, and a recent ground-level fall.",
        "clinical_data": {
          "HPI": [
            {
              "summary": "63-year-old female presented with fecal incontinence, debilitating headaches, right arm weakness, gait instability, and a recent ground-level fall.",
              "associated_symptoms": [
                "fecal incontinence",
                "debilitating headaches",
                "right arm weakness",
                "gait instability",
                "ground-level fall"
              ]
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Imaging studies revealed an 8 cm area of cerebral edema in the left parietal lobe, a 3.5 cm mass in the superior segment of the lower lobe of the right lung, numerous subcentimeter nodules throughout the lung parenchyma, and hilar lymphadenopathy.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Cerebral edema",
              "body_part": "Parietal lobe",
              "modality": "CT",
              "finding": "8 cm area of cerebral edema in the left parietal lobe",
              "date": null
            },
            {
              "type": "Mass",
              "body_part": "Lung",
              "modality": "CT",
              "finding": "3.5 cm mass in the superior segment of the lower lobe of the right lung",
              "date": null
            },
            {
              "type": "Nodule",
              "body_part": "Lung parenchyma",
              "modality": "CT",
              "finding": "numerous subcentimeter nodules throughout the lung parenchyma",
              "date": null
            },
            {
              "type": "Lymphadenopathy",
              "body_part": "Hilar",
              "modality": "CT",
              "finding": "hilar lymphadenopathy",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "CT-guided lung core needle biopsy confirmed invasive non-small cell lung carcinoma (NSCLC) with a prominent lepidic pattern.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Computed tomography",
              "body_part": "Lung",
              "modality": "CT",
              "finding": "invasive non-small cell lung carcinoma (NSCLC) with a prominent lepidic pattern",
              "impression": "invasive non-small cell lung carcinoma (NSCLC) with a prominent lepidic pattern"
            }
          ],
          "procedures": [
            {
              "name": "Lung core needle biopsy",
              "approach": "percutaneous",
              "location": "Lung"
            }
          ],
          "diagnoses": [
            {
              "code": "C0024117",
              "label": "Non-Small Cell Lung Carcinoma",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Lung mass biopsy revealed lung adenocarcinoma with a predominantly lepidic pattern. Immunohistochemical analysis showed positive staining for TTF-1, Napsin A, CK7, and CK5/6, and negative staining for CK20, P40, chromogranin, and synaptophysin. The cell proliferation index was estimated to be less than 3% via Ki-67 stains. Genpath OnkoSight histologic and tissue tumor next-generation sequencing revealed an EGFR Glu 757-Ala 750 deletion mutation, a rare exon 19 deletion variant.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "EGFR Glu 757-Ala 750 deletion mutation",
              "label": "EGFR Glu 757-Ala 750 deletion mutation",
              "status": "active"
            }
          ],
          "labs": [
            {
              "test": "TTF-1",
              "value": "positive"
            },
            {
              "test": "Napsin A",
              "value": "positive"
            },
            {
              "test": "CK7",
              "value": "positive"
            },
            {
              "test": "CK5/6",
              "value": "positive"
            },
            {
              "test": "CK20",
              "value": "negative"
            },
            {
              "test": "P40",
              "value": "negative"
            },
            {
              "test": "Chromogranin",
              "value": "negative"
            },
            {
              "test": "Synaptophysin",
              "value": "negative"
            },
            {
              "test": "Ki-67",
              "value": "<3%",
              "unit": "%",
              "flag": "normal"
            }
          ],
          "imaging": [
            {
              "type": "Lung mass",
              "modality": "biopsy",
              "finding": "Lung adenocarcinoma with a predominantly lepidic pattern"
            }
          ],
          "procedures": [
            {
              "name": "Next-generation sequencing",
              "location": "tissue tumor"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "After 17 months of treatment with osimertinib, lung mass biopsy showed lung carcinosarcoma with islands of sarcomatoid spindled cells among solid epithelioid components (H&E, 200x). Biopsy of primary lung mass at initial diagnosis (Ki-67, 200x) showed positive staining in <5% of cells. Resistance to first- and second-generation TKIs developed. Collection date 2024 Apr.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34",
              "label": "Lung cancer",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "91533001",
              "label": "Carcinosarcoma",
              "status": "active",
              "onset_date": null
            }
          ],
          "procedures": [
            {
              "name": "Biopsy",
              "approach": "other",
              "date": "2024-04",
              "location": "Lung mass",
              "performed_by": null,
              "outcome": null
            }
          ],
          "labs": [
            {
              "test": "Ki-67",
              "value": "<5%",
              "unit": "%",
              "flag": "normal",
              "reference_range": null,
              "timestamp": null
            }
          ],
          "medications": [
            {
              "drug": "Osimertinib",
              "dosage": null,
              "frequency": null,
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": "Lung cancer"
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Development of resistance to osimertinib due to acquired resistance mechanisms, including EGFR-dependent and EGFR-independent mechanisms such as acquired EGFR mutations, amplifications, genetic fusions, MAPK-PI3K mutations, cell cycle gene alterations, and histologic transformation.",
        "clinical_data": {}
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "After 17 months of treatment with osimertinib, fine-needle aspiration of 11R lymph node (Ki-67, 200x) showed Ki-67 positivity in >90% of cells.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1705934",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "procedures": [
            {
              "name": "C0154187",
              "approach": null,
              "date": null,
              "location": "C1296340",
              "performed_by": null,
              "outcome": null
            }
          ],
          "labs": [
            {
              "test": "C0877508",
              "value": ">90%",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "Patient underwent stereotactic radiosurgery (SRS) and initiated treatment with osimertinib 80 mg daily. After more than 17 months of treatment, follow-up imaging showed progressive and recurrent brain and chest lesions. Endobronchial ultrasound-guided fine-needle aspiration of the 11R lymph node confirmed a poorly differentiated malignancy consistent with metastatic carcinosarcoma. Further characterization of the metastatic recurrent lung cancer revealed a biphasic morphology with solid sheets of pleomorphic, neoplastic mesenchymal cells interspersed with small islands of neoplastic epithelial cells.",
        "clinical_data": {
          "procedures": [
            {
              "name": "Stereotactic radiosurgery",
              "date": null
            },
            {
              "name": "Endobronchial ultrasound-guided fine-needle aspiration",
              "date": null,
              "location": "11R lymph node"
            }
          ],
          "medications": [
            {
              "drug": "Osimertinib",
              "dosage": "80 mg",
              "frequency": "daily",
              "modality": "oral",
              "start_date": null,
              "end_date": null
            }
          ],
          "imaging": [
            {
              "type": "Imaging",
              "body_part": "brain",
              "finding": "progressive and recurrent brain lesions",
              "date": null
            },
            {
              "type": "Imaging",
              "body_part": "chest",
              "finding": "progressive and recurrent chest lesions",
              "date": null
            }
          ],
          "diagnoses": [
            {
              "code": "Carcinosarcoma",
              "label": "metastatic carcinosarcoma",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "Lung Cancer",
              "label": "metastatic recurrent lung cancer",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 8,
        "content": "Immunocytochemistry of 11R lymph node sample demonstrated positive staining for TTF-1, AE1/AE3, EMA, CD56, and vimentin with negative staining for CK7, P40, napsin, calretinin, PAX-8, S-100, synaptophysin, and chromogranin. Ki-67 staining revealed an estimated cell proliferation index of 90%. Foundation one next-generation sequencing identified an additional EGFR exon 19 deletion (E746_A750del) in addition to the previously identified EGFR G796C and 1744V point mutations. Notable novel mutations were also found in",
        "clinical_data": {
          "labs": [
            {
              "test": "TTF-1",
              "value": "positive",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "AE1/AE3",
              "value": "positive",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "EMA",
              "value": "positive",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "CD56",
              "value": "positive",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "Vimentin",
              "value": "positive",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "CK7",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "P40",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "Napsin",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "Calretinin",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "PAX-8",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "S-100",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "Synaptophysin",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "Chromogranin",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "Ki-67",
              "value": "90",
              "unit": "%",
              "flag": null,
              "reference_range": null,
              "timestamp": null
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "EGFR exon 19 deletion (E746_A750del)",
              "status": "active",
              "onset_date": null
            },
            {
              "code": null,
              "label": "EGFR G796C point mutation",
              "status": "active",
              "onset_date": null
            },
            {
              "code": null,
              "label": "EGFR 1744V point mutation",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Patient's initial presentation led to imaging studies."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Imaging findings prompted a CT-guided lung core needle biopsy."
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Biopsy results led to further immunohistochemical and genetic analysis."
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Patient was treated with osimertinib for 17 months, followed by a repeat lung mass biopsy.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0025598"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Development of resistance to osimertinib."
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Fine-needle aspiration of 11R lymph node after 17 months of treatment with osimertinib."
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "Patient underwent stereotactic radiosurgery (SRS) and continued treatment with osimertinib 80 mg daily. Follow-up imaging showed progressive and recurrent brain and chest lesions. Endobronchial ultrasound-guided fine-needle aspiration of the 11R lymph node was performed.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [
            "Stereotactic radiosurgery"
          ],
          "change_type": "addition",
          "target_domain": "procedure"
        }
      }
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "Immunocytochemistry of 11R lymph node sample and Foundation one next-generation sequencing were performed."
      }
    }
  ]
}